GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » EBIT

Beijing Luzhu Biotechnology Co (HKSE:02480) EBIT : HK$-271.81 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co EBIT?

Beijing Luzhu Biotechnology Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was HK$-86.37 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-271.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Luzhu Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2023 was -28.40%. Beijing Luzhu Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -42.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -4.84%.


Beijing Luzhu Biotechnology Co EBIT Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co EBIT Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
EBIT
-659.69 -809.01 -271.81

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EBIT - -763.97 -81.21 -86.37 -185.44

Competitive Comparison of Beijing Luzhu Biotechnology Co's EBIT

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's EV-to-EBIT falls into.



Beijing Luzhu Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-271.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co  (HKSE:02480) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Luzhu Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-157.548 * ( 1 - 0% )/( (551.221 + 558.199)/ 2 )
=-157.548/554.71
=-28.40 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1195.075 - 77.802 - ( 649.526 - max(0, 105.098 - 671.15+649.526))
=551.221

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1367.767 - 44.698 - ( 818.336 - max(0, 62.329 - 827.199+818.336))
=558.199

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Luzhu Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-172.742/( ( (326.18 + max(-102.267, 0)) + (496.017 + max(-47.905, 0)) )/ 2 )
=-172.742/( ( 326.18 + 496.017 )/ 2 )
=-172.742/411.0985
=-42.02 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 2.831 + 0) - (77.802 + 0 + 27.296)
=-102.267

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 3.486 + -1.1368683772162E-13) - (44.698 + 0 + 6.693)
=-47.905

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beijing Luzhu Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-271.81/5618.841
=-4.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.
Executives
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Zhang Yanping 2202 Interest of your spouse
Kong Jian 2101 Beneficial owner
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines